Should Genetic Testing Be Done in All Patients Treated With Clopidogrel and Undergoing Percutaneous Coronary Intervention?

Current Evidence for Genetic Testing in Clopidogrel-Treated Patients Undergoing Coronary Stenting

Dirk Sibbing, MD; Isabell Bernlochner, MD; Adnan Kastrati, MD

A combined dual antiplatelet treatment consisting of aspirin and the P2Y12 receptor inhibitor clopidogrel is still considered the standard of care treatment in most of the patients undergoing percutaneous coronary intervention (PCI). Numerous research studies during the last decade, however, have highlighted possible shortcomings of the oral antiplatelet agent clopidogrel, namely its large response variability resulting in an unpredictable response for the individual patient,1,2 the association of both a low3 or enhanced response4,5 with a worse clinical outcome and the dependency of individual responsiveness on nongenetic and genetic variables.6

Response by Paré and Eikelboom on p 513

Clopidogrel is a prodrug that requires bioactivation into its active thiol metabolite before it targets the P2Y12 receptor on blood platelets. In vivo bioactivation of the drug is a 2-step process that is closely linked to the cytochrome P450 (CYP) system. Different isoenzymes are responsible for clopidogrel bioactivation and among them the isoenzyme CYP2C19 was found to play a key role in this setting by contributing to both clopidogrel bioactivation steps.7 In this context, common genetic variants within the CYP2C19 gene have been the subject of considerable attention and have stimulated numerous research projects in recent years.8–14 Beyond CYP2C19, other genes involved in clopidogrel absorption, bioactivation or interplay with the blood platelet and their receptors have been associated with drug responsiveness and clinical outcome as well. Indeed, a growing body of evidence suggests a possible role of genotyping in patients undergoing coronary stenting with a view on optimizing response to P2Y12 receptor inhibitors during and after the procedure. We review available evidence on the need of individualizing antiplatelet treatment regimens in everyday clinical practice.

Genetic Determinants for Clopidogrel Response and Clinical Outcome

In recent years, multiple genetic factors within different candidate genes being involved in clopidogrel absorption, bioactivation, and platelet P2Y12 receptor interaction have been associated with both high and low platelet reactivity to this drug. Concordantly, in terms of clinical outcome measures, variants were linked to either ischemic8,13,15 or bleeding events16,17 after coronary stenting procedures.

By far, the most prominent and best established genetic factor is located within the CYP2C19 gene. The polymorphically expressed isoenzyme CYP2C19 is involved in both metabolic steps of clopidogrel’s 2-step active metabolite generation.7,18 In 2006 and probably without anticipating the momentousness of their observation, Hulot et al...
for the first time reported that a single-nucleotide polymorphism (SNP) located within the CYP2C19 gene is a major determinant of clopidogrel responsiveness in healthy subjects. Since then, several studies as well as their meta analyses have demonstrated that the presence of this common CYP2C19*2 loss-of-function allelic variant, which is associated with a complete loss of enzyme function, comes along with an attenuated response to clopidogrel and with a higher risk for ischemic events including stent thrombosis in PCI-treated patients. Selected studies with clinical end points investigating CYP2C19*2 in clopidogrel treated patients are highlighted in the Table. Our results in a large PCI cohort of patients (n=2485) as well as data from the so-far largest and most comprehensive meta analysis with patient data from more than 9000 PCI-treated patients clearly confirmed a significant impact of both homozygous and heterozygous CYP2C19*2 allele carriage on clinical outcome (see Figure 1). In line with this, platelet function studies have shown a gene-dose effect for this allelic variant with a gradual increase of ADP-induced platelet aggregation values from wild-type homozygous patients to heterozygous and over to homozygous *2 allele carriers. Concordantly, as outlined in Figure 2, the proportion of patients with high on-treatment platelet reactivity (HPR) is higher in both heterozygous and homozygous *2 allele carriers. This observation may directly affect clinical decision-making because it expands the population at risk from about 2% of patients (*2/*2 genotype) to 25% of patients (*1/*2 or *2/*2 genotype). However, it should be noted that the influence of this genetic variant appears to be confined to PCI-treated patients under clopidogrel treatment as post hoc analyses of the CURE and ACTIVE trials, in which the proportion of PCI-treated patients was very low, did not show a significant influence of this variant on clinical outcome measures. This is in line with the observation that in PCI-treated patients the risk for CYP2C19*2 allele carriers of having an ischemic event is most pronounced for the occurrence of stent thrombosis. This makes sense because the primary reason for prescribing antiplatelet treatment agents in patients undergoing coronary stenting is to avoid the closure (stent thrombosis) of the device implanted.

In contrast to CYP2C19*2, a promoter variant within the same gene, namely the CYP2C19*17 gain-of-function (GOF) allelic variant, results in increased enzyme function due to higher transcription rates of the gene and a presumed accelerated bioactivation of clopidogrel. In a study of 1524 PCI-treated patients this GOF variant was found to be associated with lower ADP-induced platelet aggregation values (enhanced response) and a substantially higher bleeding risk for CYP2C19*17 allele carriers, although a protective effect of *17 allele carriage on ischemic events was not observed. Later on, the association of *17 allele carriage and bleeding was confirmed by a genetic substudy of the PLATO trial, in which significantly more bleeding events were found in clopidogrel-treated patients than in placebo-treated patients. A similar association was found in a group of patients with acute myocardial infarction. Overall, results for CYP2C19*17 remain conflicting, with some functional and clinical studies finding an impact on clopidogrel treatment efficacy or safety and others not finding an impact. Reasons for conflicting data on CYP2C19*17 remain unclear but could be related to the small sample size in some studies but also to the circumstance that the influence of this variant should be considered as modest when compared with CYP2C19*2. However, similar as for CYP2C19*2, carriage of the GOF variant may be the reason to shift certain patients toward higher threshold values for their platelet reactivity level. Ultimately, this may cause a bleeding event in one patient, whereas it may prevent thrombotic complications in another. Besides the common *2 and *17 variants located within the CYP2C19 gene, a number of uncommon variants (*3 to *8) exist as well. Their detailed description is beyond the scope of the present manuscript and is summarized elsewhere.
Similar as for the CYP2C19 GOF variant, available data are also conflicting for another genetic marker located within the ABCB1 gene, which encodes for the enteric multidrug resistance protein 1 (MDR 1). This protein is responsible for the absorption of clopidogrel in the intestine and an influence of an SNP within the ABCB1 gene (C3435T) was first described by Taubert et al in 2006.31 Whereas some studies20,32 reported on a positive association of the ABCB1 C3435T genotype with clopidogrel treatment efficacy, other studies failed to show a significant impact of this variant on the outcome of clopidogrel-treated patients.16,29 Further studies are surely needed to confirm or to refute an impact of this variant on clopidogrel treatment efficacy.

Just recently, a single genetic variant (Q192R) within the gene encoding for the paraoxonase-1 (PON1) enzyme was linked to clopidogrel bioactivation, response to clopidogrel therapy, and the risk for stent thrombosis in clopidogrel-treated patients.33 Results of that study suggested that PON1 might be considered a key player for the second step of clopidogrel bioactivation. Surprisingly, the latter study could not confirm the well established association of CYP2C19*2 with the risk for stent thrombosis in clopidogrel-treated patients. Hence, these findings questioned the current concept of clopidogrel in vivo bioactivation and cast doubts on a large body of previous genetic association studies.8–13,15,20–22,32,34,35 These intriguing observations required external confirmation and as expected other groups of authors tried to validate these results in their cohorts of patients. We were not able to replicate these findings on PON1 Q192R genotype; neither on clopidogrel responsiveness nor on the risk for stent thrombosis.24 In line with this, the recently completed Genotype Information and Functional Testing (GIFT) trial (NCT:00992420), a platelet substudy from the GRAVITAS trial36 reported at the American College of Cardiology 2011 Scientific Sessions, also failed to find any evidence for a relevant role of PON1 in clopidogrel-treated patients. Concordantly, the first and so far only genome-wide association study on clopidogrel treatment efficacy, only reported compelling evidence for 1 major locus on chromosome 10q24 that influences clopidogrel drug response.8 The reported locus encompasses the CYP2C19 gene locus, but other loci or specifically loci including the PON1 or ABCB1 genes were not reported by the authors to be associated with clopidogrel responsiveness.

Figure 1. Hazard ratios (HRs) are reported for stent thrombosis among carriers of 1 (A) or 2 (B) CYP2C19*2 alleles versus noncarriers. Size of data markers reflects the statistical weight of the respective study in the entire meta-analysis. Data marker for the overall category (in red) shows the 95% confidence interval (CI) for the overall HR. Number of events and individuals at risk are shown for all studies included. Adapted from Mega et al,15 with permission.
setting a cutoff aggregation value at 468 AU/min, according to genotypes (wt/wt, wt/*2, *2/*2) is shown. HPR was defined by on-treatment platelet reactivity (HPR) in relation to CYP2C19*2 aggregometry (MEA). The proportion of patients with high assessed in whole blood using multiple electrode platelet function in response to adenosine diphosphate (ADP) was chronic treatment with aspirin and clopidogrel (75 mg/d). Platelet allele. Defining only homozygous *2 allele carriers as poor metabolizers. “The term “poor metabolizer status” was defined by the fact “that the drug can be less effective in people who cannot metabolize the drug to convert it to its active form.” The FDA also stated that “Tests are available to identify a patient’s CYP2C19 genotype and can be used as an aid in determining therapeutic strategy.” Moreover, it was stated that one should “consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers.” The term “poor metabolizer status” was defined by the FDA as a subject being homozygous for the CYP2C19*2 allele. Defining only homozygous *2 allele carriers as poor metabolizers with advice for a change in treatment would narrow the population at risk to approximately 2%. However, data from numerous trials as well as their meta-analyses suggest that carriage of even one single *2 allele is enough to put a patient at a significantly higher risk for ischemic events including the occurrence of stent thrombosis. Although the FDA warning was therefore justified based on the overwhelming evidence for a relevant role of CYP2C19*2 in the setting of clopidogrel treated patients (see also summary of studies in the Table), for the attending physician it is difficult to translate this advice into clinical practice. This is due to a number of reasons, including (1) genotyping assays are not available in all situations; (2) algorithms are missing and are even lacking in the FDA statement commenting on how to improve treatment in CYP2C19*2 allele carriers; and (3) that numerous genetic and nongenetic variables act in concert on clopidogrel treatment efficacy, with CYP2C19*2 being only a single part of the entire puzzle the treating physician must deal with.

In summary, a number of genetic factors are likely to act in concert on clopidogrel bioactivation and the clinical outcome of clopidogrel-treated patients. Further studies in large cohorts of patients are urgently needed to confirm or to refute a role of previously described variants in this setting and to explore new and yet unidentified genetic markers. Until then, single genetic variant stands out in playing a key role in the setting of clopidogrel treatment; namely the CYP2C19*2 loss-of-function allele. This should be the first-choice SNP to be tested when it comes to the issue of what markers should be genotyped in the individual patient.

Food and Drug Administration Black Box Warning on Clopidogrel

Discussions on the importance of genotyping in clopidogrel-treated patients undergoing PCI have been inspired by the action of US Food and Administration (FDA) in March 2010. At that time, the FDA added a boxed warning to clopidogrel to alert patients and health care professionals to the fact “that the drug can be less effective in people who cannot metabolize the drug to convert it to its active form.” The FDA also stated that “Tests are available to identify a patient’s CYP2C19 genotype and can be used as an aid in determining therapeutic strategy.” Moreover, it was stated that one should “consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers.” The term “poor metabolizer status” was defined by the FDA as a subject being homozygous for the CYP2C19*2 allele. Defining only homozygous *2 allele carriers as poor

Genetic Factors and Newer Antiplatelet Agents

Prasugrel and ticagrelor, two newer antiplatelet agents, are now available, with a more rapid and predictable mode of action. The latter characteristics are related to the pharmacological properties of both drugs, and it is vitally important to recognize that prasugrel bioactivation is less dependent on CYP system bioactivating capacities and that ticagrelor is already absorbed in its active form without any need for in vivo bioactivation. Thus, for ticagrelor, it does not come as a surprise that different studies did not observe any influence of genetic markers including CYP2C19 and ABCB1 on either the pharmacodynamic effect of the drug or the clinical outcome of ticagrelor-treated patients. Similar observations were reported for prasugrel, with no influence of common functional CYP genetic variants (including CYP2C19*2) on active metabolite generation, inhibition of platelet aggregation, or the clinical outcome of prasugrel-treated patients. Thus, current data available do not provide a rationale for routine genotyping in prasugrel- or ticagrelor-treated patients. However, it may well be that yet unknown genetic factors significantly influence prasugrel bioactivation or the interaction of prasugrel and ticagrelor with the P2Y12 receptor on blood platelets. Other clinical scenarios where genotyping in patients on prasugrel or ticagrelor may provide important information are outlined later on.

Available Assays Allowing Bedside Genotyping

For reliable genotyping of genetic variants (especially CYP2C19*2) in clopidogrel-treated patients, conventional use of laboratory-based methods such as DNA sequencing or TaqMan genotyping will be best suited primarily for research purposes. These laboratory-based methods are time consuming and require a separate step of DNA isolation beforehand. A widespread adoption of genotyping in clinical routine can only be realized in the future.
with the utilization of genotyping assays that allow point-of-care testing without any need for prior separate DNA isolation step. Requirements for these assays are that they are easy to use, provide reliable results rapidly, and are reproducible and in terms of costs that they are affordable to be used in clinical practice. At present, only two point-of-care assays are available for CYP2C19*2 genotyping: the Verigene CYP2C19 XP system (Nanosphere, Northbrook, IL) and the Spartan RX CYP2C19 system (Spartan Bioscience Inc, Ottawa, Ontario). The Verigene system uses whole blood, with a detection technology based on gold nanoparticles. It allows the genotyping of different CYP2C19 allelic variants in parallel, but the time from probe sampling to results takes about 3 hours. The Spartan system uses a buccal swab with a detection technology based on end-point PCR. In its present form, this system allows for genotyping of CYP2C19*2 only, but results are available with 1 hour after probe sampling. Further assays are under development and await introduction in research projects and clinical routine.

**Predictive Value for Estimates of Clopidogrel Response**

Undoubtedly, both genotyping and platelet function testing (that is, phenotyping) can be considered as estimates of clopidogrel response. It is a crucial point to note that numerous studies and meta-analyses have clearly demonstrated a predictive value for both genotyping and platelet function testing on the clinical outcomes of clopidogrel-treated patients undergoing PCI. Thus, in case the attending physician aims at undertaking a risk estimation for the individual patient, the evidence base is already there to do this with either genotyping and/or platelet function testing. The next logical question to be addressed would now be in how far a guidance of treatment based on either genotyping and or phenotyping is able to improve the overall clinical outcome of patients.

Initial experience on individualizing antiplatelet therapy in PCI-treated patients was gained in the GRAVITAS (Gauging Responsiveness with a VerifyNow Assay: Impact on Thrombosis and Safety) trial. Interestingly, study results failed to show a benefit of an intensified clopidogrel treatment to overcome HPR and to improve patient outcomes after PCI and prompted a discussion as to what extent the impact of platelet function testing and the need for individualizing P2Y12 receptor directed treatment is overestimated at present. However, negative study results in GRAVITAS cannot be extrapolated to the usefulness of platelet function testing and individualized treatment approaches in general. Numerous reasons may account for the disappointing results including the HPR cutoff value in GRAVITAS that led to >40% of clopidogrel low responders, the selection of a stable cohort of patients resulting in a very low event rate, the assay used for testing that lacked a predictive value in the observational arm of GRAVITAS and—most likely—the fact that only intensifying clopidogrel treatment is not sufficient to overcome HPR in this cohort. Similar reasons may have accounted for the circumstance that the TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study (NCT00910299) was stopped prematurely with an unexpected low rate of primary end point events and due to a low recruitment rate.

**Individualized Treatment Approaches**

In patients presenting with acute coronary syndromes (ACS), both prasugrel in TRITON-TIMI 38 and ticagrelor in PLATO were found to be superior to clopidogrel in terms of clinical efficacy. With the advent of these more potent and predictably acting drugs that target the P2Y12 receptor, the prerequisite for an individualized approach for tailored antiplatelet treatment is set. It could be a possible approach to use these potent drugs for all patients undergoing coronary stenting procedures. Not surprisingly, however, the risk reduction for thrombotic events observed with both prasugrel and ticagrelor comes at the costs of a higher bleeding risk. Correspondingly, evidence for the existence of a “sweet spot” or therapeutic window of P2Y12 receptor inhibition is not only based on clinical outcome data from large-scale trials but can also be found at the level of platelet function testing. These multiple lines of evidence raise the question by which means (genotyping and/or phenotyping) patients could be identified that may benefit most from potent P2Y12 receptor inhibitors. Certainly, there is no single answer to the question in how far genotyping is superior to phenotyping or vice versa. More likely, advantages or disadvantages of one or the other approach will be closely related to the clinical scenario where testing is done.

Noteworthy, post-PCI events (especially stent thromboses) can occur very early after the index procedure. Thus, when considering scenarios favoring a genotyping only or combined phenotyping/genotyping approach the time necessary for genotyping and/or phenotyping must be considered. It takes some minutes with available point-of-care devices to obtain phenotyping results on clopidogrel responsiveness and about an hour or longer to obtain genotyping results with currently available genotyping assays (see section on “available assays allowing bedside genotyping”). This time window necessary may miss the key window of risk in some acute patients.

**I. Scenarios Favoring a Genotyping Approach**

At present, the best available evidence for individualizing P2Y12 inhibitor treatment and a possible role of genotyping in this setting comes from TRITON–TIMI 38. In fact, for the primary end point of the trial (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke) the overall risk was comparable in prasugrel-treated patients from the entire cohort (n=6813) to clopidogrel-treated patients (n=1064) who were noncar-
riers of the CYP2C19*2 allele (9.9% versus 8.0%, respectively). A similar risk relationship was observed for the occurrence of stent thrombosis in TRITON-TIMI 38 and the genetic substudy (1.1% in the prasugrel cohort versus 0.8% in clopidogrel-treated noncarriers). In other words, and from a more provocative point of view, knowing the CYP2C19*2 genotype of an individual patient may render it unnecessary to use a more potent antiplatelet agent such as prasugrel when keeping in mind the bleeding risk associated with the drug.

In certain clinical scenarios, genotyping alone may help guiding antiplatelet treatment of P2Y12 receptor targeting drugs. This could be the case in the run-up to high-risk coronary stenting procedures such as planned left-main stenting or multiple vessel stenting, in which genotyping beforehand may allow for roughly predicting the presumed response to standard clopidogrel treatment before intake of the drug. Patients could then be pretreated with an intensified antiplatelet treatment regimen in preparation to the procedure. Specifically for CYP2C19*2 homozygous patients, more potent drugs such as prasugrel or ticagrelor may be a better first choice treatment option because about 1 of 2 patients (see Figure 2) in this specific cohort exhibit a high on-clopidogrel treatment platelet reactivity, which cannot be overcome in all of them by just intensifying the dose of clopidogrel. In addition, when platelet function assays are unavailable or when patients are under the influence of GP IIb/IIIa receptor inhibitors, which obviates the possibility to assess clopidogrel response for most available assays, genotyping may provide prompt information on clopidogrel bioactivation capacities. Further clinical scenarios could be assumed in patients on ticagrelor or prasugrel treatment, also keeping in mind that their response to clopidogrel cannot be assessed with platelet function testing at that time. Regardless of whether their primary ischemic event was considered as an ACS or not some patients may have bleeding events or from clinically relevant side effects of the respective drug. In addition, contraindications may become obvious or may arise before or while being on drug treatment that preclude from continuing further drug administration. Latter aspects may directly affect morbidity and mortality risk but may also be a cause for noncompliance in the individual patient, and a clinical decision must be made whether or not to switch them over to clopidogrel. Non-CYP2C19*2 carriers would be excellent candidates to switch in such situations because their risk for HPR on clopidogrel is lowest (see also Figure 2). Moreover, genotyping could play a role during a clinical risk profile assessment for PCI-treated patients in general but specifically for patients with a history of prior stent thrombosis. In this instance, questions always arise in how far this event may have been related to technical shortcomings at the index procedure (eg, stent underexpansion) or to treatment failure of the prescribed antiplatelet treatment.

Finally, when considering the usefulness of genetic testing from an economic point-of-view, it is important to consider that clopidogrel is already available in a generic version in many countries now. This may play a role in selected cases when one considers the higher daily therapy costs for newer antiplatelet agents such as prasugrel or ticagrelor.

II. Scenarios Favoring a Combined Phenotyping/Genotyping Approach

One must be aware, however, of the circumstance that a major shortcoming of genotyping alone is surely the uncertainty with which the clopidogrel response is predicted as the determined genotype can never surely predict the clopidogrel responder phenotype. This means, for example, that patients across all CYP2C19*2 genotypes (wt/wt or wt/*2 or *2/*2) could end up as enhanced, normal, or low responders to clopidogrel. Thus, a combined approach of both genotyping and simultaneous platelet function testing may show the greatest promise and certainty for future guidance of tailored antiplatelet treatment. The Thromboocyte Activity Reassessment and GEnoTyping for PCI (TARGET-PCI) trial (ClinicalTrials.gov Identifier: NCT01177592) is currently addressing this issue with a combined approach of platelet function testing and genotyping (including the determination of CYP2C19*2 carrier status). Other ongoing studies that try to prove the concept in how far a genotyping-guided approach may improve the outcome of PCI-treated patients in need of sufficient P2Y12 receptor inhibition are the Genotyping Infarct Patients to Adjust and Normalize Thienopyridine Treatment (GIANT) trial (ClinicalTrials.gov Identifier: NCT01134380) and the Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study (GeCCO) (ClinicalTrials.gov Identifier: NCT00995514).

In general, it seems unlikely that genotyping could be expected to substitute for platelet function testing, as only the latter reflects the influence of all extrinsic (eg, comedication) and intrinsic (eg, genetic variants) variables that act in concert on clopidogrel bioactivation and ultimately on the measured response to the drug. Moreover, it was shown that a CYP2C19*2 carrier status could only account for about 5% of the antiplatelet response to clopidogrel. However, genotyping can provide important confirmatory information for platelet function testing results when it comes to the question in how far an observed low responder status to clopidogrel is likely to be stable over time or not. Clinical scenarios may also exist, where platelet function testing only reflects a snapshot of the patient’s platelet reactivity, which is subject to change over time. In ACS patients, for example, platelets are highly activated during the event and are likely to settle to a more quiescent state later on. Genotyping may help to better distinguish durability or instability of a measured platelet response. Thus, in everyday clinical practice a
A step-by-step approach may prove useful where the phenotype is determined contemporary to the PCI procedure by platelet function testing and genotyping could be performed later on before the patient is discharged. The combined information may help to find the best treatment for the individual patient during (a) the acute phase surrounding the procedure and (b) for the chronic phase of treatment that follows. It may be well that different time periods for the individual patient may long for different potency levels of the prescribed P2Y12 receptor inhibitor. A patient may need more potent drugs such as prasugrel or ticagrelor in the acute setting but may be efficiently treated with clopidogrel later on.

Reflecting the growing body of evidence for a predictive value of both genotyping and platelet function testing in clopidogrel-treated patients undergoing coronary stenting, recently updated “ACCF/AHA Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction” now include new class Ib recommendations for both approaches (level of evidence: B for platelet function testing, level of evidence: C for CYP2C19*2 genotyping). With randomized studies including genotyping-directed treatment options still lacking, these guideline recommendations offer the treating physician some reassurance in case one opts to change treatment, based on testing results. Clinical scenarios where genotyping or combined genotyping/phenotyping may help to guide antiplatelet treatment are summarized in Figure 3.

Concluding Remarks
It was in 1999 and 2 years after the approval of the second-generation thienopyridine clopidogrel by the FDA, when the first case of clopidogrel treatment failure was reported in the literature. Since then, it took more than a decade to elucidate the drug’s pharmacological and pharmacogenetic properties. Nowadays, we all know that the drug works well in most but not in all patients and the phenomenon of clopidogrel response variability as well as its association with genetic variants is well perceived. More potent drugs such as prasugrel or ticagrelor are available, and an individualized approach of antiplatelet treatment seems logical in this circumstance. Different clinical scenarios may favor a genotyping approach only, but in most scenarios the comprehensive information received from both phenotyping and genotyping will provide the perception necessary to build treatment decisions on.

Disclosures
Dr Sibbing received research grants from Cordis, Medtronic, Eli Lilly, PGXHealth, Accumetrics, and Dynabyte and consulting fees and honoraria from Daiichi Sankyo/Lilly, AstraZeneca, The Medicines Company, and Dynabyte.

References


Response to Sibbing, Bernlochner and Kastrati

Guillaume Paré, MD, MSc; John W. Eikelboom, MBBS, MSc

We agree with Sibbing and colleagues that *CYP2C19* loss-of-function alleles are a determinant of pharmacodynamic response to clopidogrel and clinical outcome. Evidence of association is, however, insufficient to justify the introduction of a new laboratory test into routine clinical practice; we also need evidence that a therapeutic strategy based on the results of testing will yield worthwhile benefits for patients. In the case of *CYP2C19* genetic testing, there are strong grounds to expect that any benefit of testing will be modest and difficult to demonstrate. First, compared with clinical risk factors, genetic determinants of response are a relatively minor determinant of risk of cardiovascular events following PCI; for example, lack of compliance with clopidogrel therapy is far more important and is also potentially modifiable. Second, *CYP2C19* loss-of-function alleles account for only a small fraction of the heritability of clopidogrel response; other genetic polymorphisms appear to account for most of the response variability but are as yet undiscovered. Third, because any impact of *CYP2C19* polymorphisms is likely to be small, distinguishing their effects from those of potential confounders will require an adequately powered randomized controlled trial that will be costly and logistically challenging. We agree that individualizing antiplatelet therapy according to the results of laboratory testing is an attractive and exciting concept but the utility of this approach remains unproven and has not been supported by recent trial results (eg, GRAVITAS, TRIGGER PCI). Until such times, we believe that the best outcomes for patients will be obtained by basing treatment decisions on the overall results of large randomized controlled trials.
Current Evidence for Genetic Testing in Clopidogrel-Treated Patients Undergoing Coronary Stenting
Dirk Sibbing, Isabell Bernlochner and Adnan Kastrati

Circ Cardiovasc Interv. 2011;4:505-513
doi: 10.1161/CIRCINTERVENTIONS.111.962183
Circulation: Cardiovascular Interventions is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2011 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-7640. Online ISSN: 1941-7632

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circinterventions.ahajournals.org/content/4/5/505

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Cardiovascular Interventions can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Cardiovascular Interventions is online at:
http://circinterventions.ahajournals.org//subscriptions/